Abstract:Key PointsSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase that has long been thought to exclusively mediate signalling by receptors of the adaptive immune response (B cell receptors (BCRs) and Fc receptors (FcRs)). However, recent studies indicate that it also participates in innate immunity and non-immune functions.SYK activation proceeds through binding of its two SRC homology 2 (SH2) domains to phosphorylated tyrosine residues in immunoreceptor tyrosine-based activation motifs (ITAMs) or ITAM-like sequences in C-type lectins. Binding to phosphorylated ITAMs relieves SYK from an intramolecular autoinhibition and triggers its association with receptor-proximal signalling molecules.SYK mediates integrin signalling in neutrophils, macrophages and platelets, signalling by P-selectin glycoprotein ligand 1 (PSGL1), as well as the development of osteoclasts. These responses are mediated by ITAM-containing adaptor molecules (mostly DAP12 and FcRγ).SYK participates in innate recognition of fungal and other microbial pathogens, as well as of tissue damage, by C-type lectins. SYK activation by C-type lectins activates the caspase-recruitment domain 9–B cell lymphoma 10–mucosa-associated lymphoid tissue lymphoma translocation protein 1 (CARD9–BCL-10–MALT1) pathway and it is also required for NLR family, pyrin domain-containing 3 (NLRP3) inflammasome activation following fungal infection.The phosphorylated ITAM-mediated activation of the SYK homologue SH2 domain ankyrin repeat kinase (SHARK) is required to remove cellular debris in Drosophila melanogaster. This finding indicates an ancient origin of the ITAM–SYK signalling pathway.SYK is required for the separation of newly formed lymphatic vessels from the blood vasculature. This function is probably mediated by the SYK-coupled receptor CLEC2 in platelets.SYK has a central role in the development of allergic and autoimmune diseases, as well as in haematological malignancies such as B cell lymphomas. A new SYK inhibitor has shown beneficial effects in human rheumatoid arthritis and B cell lymphomas.

Current understanding of the role of tyrosine kinase 2 signaling in immune responses

Therapeutic Potential of Tyrosine Kinase 2 in Autoimmunity.

Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review

Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors

Tyrosine Kinase 2 Inhibitors: Synthesis and Applications in the Treatment of Autoimmune Diseases

The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL

Essential Kinases And Transcriptional Regulators And Their Roles In Autoimmunity

Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases

TYK2: an emerging therapeutic target in rheumatic disease

TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes

Tyrosine kinase 2 inhibitors in autoimmune diseases

Advancements in Tyrosine Kinase-Mediated Regulation of Innate Nucleic Acid Sensing.

Recent progress on tyrosine kinase 2 JH2 inhibitors

TYK2: An Upstream Kinase of STATs in Cancer

Tbk1, A Central Kinase In Innate Immune Sensing Of Nucleic Acids And Beyond

Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling

Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases

The SYK tyrosine kinase: a crucial player in diverse biological functions

TANK-Binding Kinase 1-Dependent Responses in Health and Autoimmunity

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus